merged_colon-cancer-blood-test-shield.txt
<question_number>1</question_number>
<answer>Unlike other screening tests for colon and rectal cancers, the Shield test has a poor record of finding precancerous growths (only 13% compared to 95% with a colonoscopy).</answer>

<question_number>2</question_number>
<answer>If the Shield test indicates that the person might have colorectal cancer or a large polyp, they will need a colonoscopy procedure to find and remove the cancer or polyp.</answer>

<question_number>3</question_number>
<answer>The Shield test is simple for patients - the blood sample can be obtained at a doctor's office as part of a routine physical exam, or at a commercial lab, which is easier than the preparation required for a colonoscopy.</answer>

<question_number>4</question_number>
<answer>The Shield test's ability to find cancers when they are early stage and usually curable (87% of early-stage cancers) contradicts the typical goal of colorectal cancer screening methods to also find and remove precancerous growths to prevent cancer.</answer>

<question_number>5</question_number>
<answer>The FDA advisory committee recommended approval of the Shield test because it may prompt people who forget or avoid colorectal cancer screening to be screened, despite cautioning that its inability to prevent cancer is a serious limitation.</answer>

<question_number>6</question_number>
<answer>The Shield test takes advantage of the fact that cancer cells and large polyps shed fragments of DNA into the blood, which aligns with the challenges faced by other screening methods, but its poor record of finding precancerous growths introduces a new limitation.</answer>

<question_number>7</question_number>
<answer>The Shield test's poor record of finding precancerous growths (only 13% compared to 95% with a colonoscopy) contradicts the typical expectations for a cancer screening tool's preventive capabilities.</answer>

<question_number>8</question_number>
<answer>The Shield test's simplicity for patients, as the blood sample can be obtained easily, aligns with the challenges of current screening methods, but its poor record of finding precancerous growths potentially creates a new obstacle in cancer prevention.</answer>

<question_number>9</question_number>
<answer>The main limitation of the Shield test compared to other screening tests for colon and rectal cancers is that it has a poor record of finding precancerous growths.</answer>

<question_number>10</question_number>
<answer>The FDA advisory committee recommended approval of the Shield test despite its limitations because it may prompt people who forget or avoid colorectal cancer screening to be screened.</answer>